Here’s why Cramer thinks defense stock L3Harris Technologies is a buy

Here’s why Cramer thinks defense stock L3Harris Technologies is a buy


Jim Cramer says it's time to 'pounce' on this defense stock

CNBC’s Jim Cramer on Thursday gave investors his blessing to buy shares of L3Harris Technologies, an aerospace and defense play.

“Recently, the stock’s come down dramatically from its highs. I think it’s gotten to levels where you have to pounce,” he said.

Cramer said that the stock, which he’s liked since three years ago when Harris Corp and L3 Technologies merged into one firm, is also particularly attractive right now because it’s fairly recession proof. 

“They’re not tied to the consumer at all or even the enterprise. They feed at the federal trough, meaning they don’t have to care too much about the broader economy,” he said.

He added that the stock has come down dramatically since its highs in March, when Russia’s invasion of Ukraine propelled the stock from $210 to just under $280. The stock closed at $227.53 on Thursday.

Cramer did acknowledge that the company is contending with supply chain issues. CEO Christopher Kubasik in July cited supply chain disruptions as a headwind to its top line in the company’s second-quarter letter to shareholders. 

However, Cramer said that he’s still bullish on L3Harris Technologies long-term, especially because of the demand that Russia’s invasion of Ukraine will likely create for governments looking to replenish their arsenals after sending aid to Ukraine.

“In the end, L3Harris is a company with some real short-term woes, but it’s also winning big long-term business that should pay off in 2023 and 2024,” he said.

Jim Cramer’s Guide to Investing

Click here to download Jim Cramer’s Guide to Investing at no cost to help you build long-term wealth and invest smarter.



Source

FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi
Business

FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi

Signage outside Johnson & Johnson offices in Irvine, California, US, on Friday, Oct. 10, 2025. Kyle Grillot | Bloomberg | Getty Images Johnson & Johnson on Wednesday said the U.S. Food and Drug Administration approved its once-daily psoriasis pill, the first oral option to rival best-selling shots. The FDA approved the pill, Icotyde, to treat […]

Read More
Macy’s store revamp shows progress, but company expects sales to fall this year
Business

Macy’s store revamp shows progress, but company expects sales to fall this year

Macy’s on Wednesday beat Wall Street’s quarterly sales and profit expectations as its namesake brand showed signs of progress, yet still gave a cautious outlook for the year ahead. For the fiscal year, the company – which includes its namesake chain, higher-end department store Bloomingdale’s and beauty retailer Bluemercury – said it expects sales of […]

Read More
Disney embarks on new chapter as Josh D’Amaro takes over as CEO
Business

Disney embarks on new chapter as Josh D’Amaro takes over as CEO

Larissa Manoela and Josh D’Amaro, Chairperson of Walt Disney Parks and Resorts, wave to the audience after Panel Disney Experiences during Day 2 of the D23 Brazil: A Disney Experience at Transamerica Expo Center on November 09, 2024 in Sao Paulo, Brazil. Ricardo Moreira | Getty Images Disney is turning the page on a new […]

Read More